VCM
RXRX icon

Versant Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Versant Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-123
Closed -$503 – 2836
2025
Q4 		$503 Buy
123
+69
+128% +$342 ﹤0.01% 2586
2025
Q3 		$264 Buy
54
+37
+218% +$194 ﹤0.01% 2596
2025
Q2 		$86 Sell
17
-1,218
-99% -$5.98K ﹤0.01% 2619
2025
Q1 		$6.53K Buy
1,235
+54
+5% +$394 ﹤0.01% 1920
2024
Q4 		$7.98K Buy
1,181
+1,034
+703% +$6.95K ﹤0.01% 1526
2024
Q3 		$969 Buy
+147
New +$1.05K ﹤0.01% 1749

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Versant Capital Management's RXRX Position: Q1 2026 in Review

Versant Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 123 shares — an estimated $503 sold.

Versant Capital Management first reported a position in RXRX in Q3 2024 and held it in 6 quarters. The position peaked at $7.98K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Versant Capital Management reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Versant Capital Management sold 123 Recursion Pharmaceuticals shares in Q1 2026, an estimated $503.
  • Versant Capital Management first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Versant Capital Management's Recursion Pharmaceuticals position peaked at $7.98K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Versant Capital Management's 13F filing for Q1 2026, filed 7 Apr 2026.